Imatinib: all 408 studies that test it
Page 3 of 5. Open to participants first (29), then studies with results posted, then the rest; newest registration first within each.
- A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)CompletedNCT01751919Phase 1
- Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the InvestigatorCompletedNCT01742299Phase 4
- Ipilimumab and Imatinib Mesylate in Advanced CancerCompletedNCT01738139Phase 1
- Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML PatientsCompletedNCT01578213Phase 4
- Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell DiseaseWithdrawnNCT01568645Phase 1
- Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse SclerodermaTerminatedNCT01545427Phase 2
- Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDIActive, not recruitingNCT01541709Phase 2
- Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male VolunteersCompletedNCT01504984Phase 1
- Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVEStatus unknownNCT01491763Phase 4
- Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT01483014Phase 2
- Drug-drug Interaction Study With Metformin and ImatinibCompletedNCT01404715Phase 1
- Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to ImatinibStatus unknownNCT01400074Phase 3
- Glivec in Prostate Cancer Patients With Rising PSA Following Radical ProstectomyCompletedNCT01316458Phase 2
- Imatinib in KIT-negative Systemic MastocytosisCompletedNCT01297777Phase 4
- A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GISTCompletedNCT01294202Phase 2
- Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal CancerTerminatedNCT01271166Phase 1
- Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorCompletedNCT01267695Phase 2
- A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid LeukemiaCompletedNCT01227356Phase 2
- Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid LeukemiaStatus unknownNCT01227135Phase 2
- Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)SuspendedNCT01222013Phase 2
- Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)Status unknownNCT01221376Phase 2
- An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular EndpointsCompletedNCT01216085Phase 2
- RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.WithdrawnNCT01188889Phase 1/2
- Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent ChordomaStatus unknownNCT01175109Phase 1
- Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)CompletedNCT01172548Phase 2
- Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile DuctCompletedNCT01153750Phase 2
- Study to Evaluate Imatinib in Desmoid TumorsCompletedNCT01137916Phase 2
- A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid LeukemiaCompletedNCT01126814Phase 1/2
- Treatment of Polycythemia Vera With GleevecCompletedNCT01120821Phase 2
- Late Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01092741Phase 2
- Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT01085617
- Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01083589Phase 2
- Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.TerminatedNCT01066468Phase 1
- Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic CancerCompletedNCT01048320Phase 1
- Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational StudyCompletedNCT01025505Phase 2
- A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)WithdrawnNCT01011998Phase 2
- Autologous Transplantation for Chronic Myelogenous LeukemiaCompletedNCT01003054Phase 2
- Treatment of Patients With Nephrogenic Systemic Fibrosis With GlivecCompletedNCT00981942Phase 3
- A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal TumorsCompletedNCT00940563Phase 2
- Imatinib in Patients With Desmoid Tumor and ChondrosarcomaCompletedNCT00928525Phase 2
- Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive MeningiomaStatus unknownNCT00904735Phase 2
- Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic MelanomaCompletedNCT00881049Phase 2
- Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib TherapyCompletedNCT00858806Phase 2
- Glivec in Pediatric Chronic Myeloid Leukemia (CML)CompletedNCT00845221Phase 4
- Efficacy of Imatinib Mesylate in Hypereosinophilic SyndromesCompletedNCT00787384Phase 2
- Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00769327Phase 2
- Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal TumorCompletedNCT00764595Phase 2
- Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL PositiveCompletedNCT00763763Phase 2
- A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host DiseaseCompletedNCT00760981Phase 1
- Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)CompletedNCT00744081Phase 2
- Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy VolunteersCompletedNCT00732784Phase 1
- High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)CompletedNCT00707408Phase 2
- Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00686218Phase 1
- Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal TumorStatus unknownNCT00685828Phase 3
- Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00618501Phase 2
- Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant GliomaCompletedNCT00613054Phase 1
- Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach CancerCompletedNCT00601510Phase 1
- A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid LeukemiaWithdrawnNCT00594555Phase 2
- Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal TumorsTerminatedNCT00573404Phase 1
- Low-Dose Oral Imatinib for Scleroderma Pulmonary InvolvementStatus unknownNCT00573326Phase 2
- Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia PatientsTerminatedNCT00558961Phase 1/2
- A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant MesotheliomaStatus unknownNCT00551252Phase 2
- An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00538109Not applicable
- Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic PhaseCompletedNCT00514969Phase 2
- Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)CompletedNCT00514488Phase 3
- Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid LeukemiaCompletedNCT00511303Phase 2
- Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)TerminatedNCT00511121Phase 2
- Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT00510926Phase 2
- Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib MesylateCompletedNCT00510354Phase 4
- Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GISTCompletedNCT00500188Phase 2
- Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00483366Phase 1
- Efficacy and Safety of Imatinib in SclerodermaCompletedNCT00479934Phase 2
- Ph II Study of Perifosine Plus Gleevec for Patients With GISTCompletedNCT00455559Phase 2
- Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic SyndromesCompletedNCT00451997Phase 2
- Effect of a Proton Pump Inhibitor on Gleevec® in Healthy VolunteersCompletedNCT00446004Phase 1
- Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With ImatinibCompletedNCT00441155Phase 1
- Effects of Imatinib Mesylate in Polycythemia VeraCompletedNCT00430066Phase 2
- Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT00428909Phase 1
- Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath TumorsTerminatedNCT00427583Phase 2/3
- Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass PollenCompletedNCT00426179Phase 1/2
- Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00425646Phase 2
- Effect of Food on Bioavailability of a Modified Release Formulation of ImatinibCompletedNCT00422825Phase 1
- Imatinib in Adult Patients With Metastatic Ocular MelanomaTerminatedNCT00421317Phase 2
- Effect of Food on Bioavailability of Modified Release Formulations of ImatinibCompletedNCT00420043Phase 1
- Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell TumorsCompletedNCT00417807Phase 1/2
- Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular DegenerationWithdrawnNCT00403156Phase 1
- Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant MesotheliomaCompletedNCT00402766Phase 1
- A Study of Everolimus in Combination With Imatinib in Metastatic MelanomaTerminatedNCT00402662Phase 2
- Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant GliomaCompletedNCT00401024Phase 1
- Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid LeukaemiaCompletedNCT00390897Phase 4
- Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid TumorsCompletedNCT00390156Phase 1
- Glivec in Ph Positive Lymphoblastic LeukemiaCompletedNCT00388895Phase 2
- Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant GliomaCompletedNCT00387933Phase 1
- Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia PatientsCompletedNCT00386373Not applicable
- STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic LeukemiaCompletedNCT00376467Phase 2
- Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast CancerCompletedNCT00372476Phase 4
- Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid CarcinomaTerminatedNCT00354523Phase 1/2
- Imatinib Mesylate and Temozolomide in Treating Patients With Malignant GliomaCompletedNCT00354068Phase 1
- Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic PhaseStatus unknownNCT00327262Phase 3
- Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney CancerTerminatedNCT00323791Phase 2